Literature DB >> 26948173

Sentinel node biopsy versus elective neck dissection. Which is more cost-effective? A prospective observational study.

Josué Hernando1, Pedro Villarreal2, Francisco Álvarez-Marcos3, Luís García-Consuegra4, Lorena Gallego4, Luís Junquera4.   

Abstract

OBJECTIVE: The aim of this prospective not randomized observational study was to determine the costs and outcomes of sentinel lymph node biopsy (SNB) vs elective neck dissection (END) among patients with early oral squamous cell carcinoma (OSCC).
MATERIALS AND METHODS: Seventy-three consecutive patients were divided according to neck staging method. Patients took the decision themselves after receiving detailed information of both suggested treatment tools. False negative (FN) and negative predictive value (NPV) were assessed. Log-rank test was used to compare disease-free survival (DFS) and overall survival (OS). Only direct costs were analysed. Cost information derived from volumes for hospital stay, surgery and neck outcome were obtained from an internal database of tertiary health care center.
RESULTS: Thirty-two patients underwent SNB and 41 underwent an END (levels I-III). Average follow-up time was 48.2 months (range 7-80). Five neck recurrences were recorded in the SNB group (range 11-21). Seven neck recurrences occurred in the END group (range 9-16). No significant differences were found in DFS or OS. True negative patients in SNB group incurred in 42% less costs than END group. FN regardless of radiotherapy, was also lower in the SNB group. However, pN+ patients generated 23% more costs in the SNB group.
CONCLUSION: In this not randomized observational study with an average follow-up period of 48.2 months, SNB appear to confer less cost than END, with similar prognosis.
Copyright © 2016 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cost; Elective neck dissection; Oral squamous cell carcinoma; Sentinel node biopsy

Mesh:

Year:  2016        PMID: 26948173     DOI: 10.1016/j.jcms.2016.01.017

Source DB:  PubMed          Journal:  J Craniomaxillofac Surg        ISSN: 1010-5182            Impact factor:   2.078


  5 in total

1.  [68Ga]Ga-tilmanocept PET/CT lymphoscintigraphy: a novel technique for sentinel lymph node imaging.

Authors:  Rutger Mahieu; Gerard C Krijger; F F Tessa Ververs; Remmert de Roos; Remco de Bree; Bart de Keizer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-04       Impact factor: 9.236

2.  Diagnostic Efficacy of Sentinel Lymph Node Biopsy in Early Oral Squamous Cell Carcinoma: A Meta-Analysis of 66 Studies.

Authors:  Muyuan Liu; Steven J Wang; Xihong Yang; Hanwei Peng
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.240

Review 3.  Novel Diagnostic Approaches for Assessment of the Clinically Negative Neck in Head and Neck Cancer Patients.

Authors:  Daphne A J J Driessen; Tim Dijkema; Willem L J Weijs; Robert P Takes; Sjoert A H Pegge; Patrik Zámecnik; Adriana C H van Engen-van Grunsven; Tom W J Scheenen; Johannes H A M Kaanders
Journal:  Front Oncol       Date:  2021-02-05       Impact factor: 6.244

4.  Efficacy of different sentinel lymph node biopsy protocols in oral squamous cell carcinoma: Systematic review and meta-analysis.

Authors:  Maria Suárez Ajuria; Mercedes Gallas Torreira; Abel García García; Xabier Marichalar Mendía; Cintia M Chamorro Petronacci; Elena Padín Iruegas; Mario Pérez Sayáns
Journal:  Head Neck       Date:  2022-03-31       Impact factor: 3.821

5.  Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort.

Authors:  Iain L Hutchison; Fran Ridout; Sharon M Y Cheung; Allan Hackshaw; Neil Shah; Peter Hardee; Christian Surwald; Janavikulam Thiruchelvam; Leo Cheng; Tim K Mellor; Peter A Brennan; Andrew J Baldwin; Richard J Shaw; Wayne Halfpenny; Martin Danford; Simon Whitley; Graham Smith; Malcolm W Bailey; Bob Woodwards; Manu Patel; Joseph McManners; Chi-Hwa Chan; Andrew Burns; Prav Praveen; Andrew C Camilleri; Chris Avery; Graham Putnam; Keith Jones; Keith Webster; William P Smith; Colin Edge; Iain McVicar; Nick Grew; Stuart Hislop; Nicholas Kalavrezos; Ian C Martin
Journal:  Br J Cancer       Date:  2019-10-15       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.